[go: up one dir, main page]

WO2006108128A3 - Ocular delivery of interferon-tau - Google Patents

Ocular delivery of interferon-tau Download PDF

Info

Publication number
WO2006108128A3
WO2006108128A3 PCT/US2006/012980 US2006012980W WO2006108128A3 WO 2006108128 A3 WO2006108128 A3 WO 2006108128A3 US 2006012980 W US2006012980 W US 2006012980W WO 2006108128 A3 WO2006108128 A3 WO 2006108128A3
Authority
WO
WIPO (PCT)
Prior art keywords
tau
interferon
ocular delivery
ocular
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/012980
Other languages
French (fr)
Other versions
WO2006108128A2 (en
Inventor
Chih-Ping Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pepgen Corp
Original Assignee
Pepgen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pepgen Corp filed Critical Pepgen Corp
Priority to CA002602850A priority Critical patent/CA2602850A1/en
Priority to JP2008505560A priority patent/JP2008534690A/en
Priority to AU2006232130A priority patent/AU2006232130A1/en
Publication of WO2006108128A2 publication Critical patent/WO2006108128A2/en
Publication of WO2006108128A3 publication Critical patent/WO2006108128A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Methods for treating ocular disorders and systemic diseases by administering interferon-tau to the eye are described.
PCT/US2006/012980 2005-04-05 2006-04-05 Ocular delivery of interferon-tau Ceased WO2006108128A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002602850A CA2602850A1 (en) 2005-04-05 2006-04-05 Ocular delivery of interferon-tau
JP2008505560A JP2008534690A (en) 2005-04-05 2006-04-05 Interferon-tau intraocular delivery
AU2006232130A AU2006232130A1 (en) 2005-04-05 2006-04-05 Ocular delivery of interferon-tau

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66868505P 2005-04-05 2005-04-05
US60/668,685 2005-04-05

Publications (2)

Publication Number Publication Date
WO2006108128A2 WO2006108128A2 (en) 2006-10-12
WO2006108128A3 true WO2006108128A3 (en) 2007-03-29

Family

ID=37074105

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/012980 Ceased WO2006108128A2 (en) 2005-04-05 2006-04-05 Ocular delivery of interferon-tau

Country Status (4)

Country Link
JP (1) JP2008534690A (en)
AU (1) AU2006232130A1 (en)
CA (1) CA2602850A1 (en)
WO (1) WO2006108128A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033607A1 (en) * 1996-03-15 1997-09-18 University Of Florida Orally-administered interferon-tau compositions and methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033607A1 (en) * 1996-03-15 1997-09-18 University Of Florida Orally-administered interferon-tau compositions and methods

Also Published As

Publication number Publication date
WO2006108128A2 (en) 2006-10-12
JP2008534690A (en) 2008-08-28
CA2602850A1 (en) 2006-10-12
AU2006232130A1 (en) 2006-10-12

Similar Documents

Publication Publication Date Title
WO2008029276A3 (en) Compositions and methods for the treatment of ophthalmic disease
WO2009089036A3 (en) Therapeutic compositions for treatment of ocular inflammatory disorders
WO2007104541A3 (en) Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
MX2010003774A (en) Aqueous ophthalmic formulations.
WO2007022506A3 (en) Methods and compositions for treating neurological disease
EP2002841A4 (en) Ophthalmic composition comprising xanthan gum and glucose
WO2007076360A8 (en) (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
WO2005076998A3 (en) Rnai therapeutics for treatment of eye neovascularization diseases
WO2007136759A3 (en) Method for the treatment and prevention of ocular disorders
WO2006044860A3 (en) Thiadiazole compounds and methods of use
WO2007084684A3 (en) Therapeutic uses of inhibitors of rtp801
WO2010048332A3 (en) Compounds for treating ophthalmic diseases and disorders
WO2008060362A3 (en) Methods and compositions for the treatment of skin diseases and disorders
WO2006058868A8 (en) Substituted pteridines for treating inflammatory diseases
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
WO2007098106A3 (en) Respiratory tract delivery of interferon-tau
WO2009109616A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxrl and p40
EP1940373A4 (en) Inositol derivatives and their uses in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence
WO2010028088A3 (en) Sulfur-linked compounds for treating opthalmic diseases and disorders
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
WO2014161004A3 (en) Compositions and methods for the delivery of drugs to the ocular surface by contact lenses
WO2013189606A3 (en) Interval therapy for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006232130

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2602850

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2006232130

Country of ref document: AU

Date of ref document: 20060405

Kind code of ref document: A

Ref document number: 2008505560

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020077024350

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06740694

Country of ref document: EP

Kind code of ref document: A2